This call for tenders aims to speed up the development of a point-of-care diagnostic medical device that can provide antimicrobial susceptibility results on the bacteria or fungi causing an infection in humans, within one hour or less from subject sample collection, and ideally, to also allow for pathogen identification. By the end of the contract, the product developed should aim at reaching system complete and qualified (TRL 8). 

IHI call 10 will be a standard, two-stage call for proposals with the following topics:

• Digital label: one source of comprehensive information for medical technology products
• Safeguarding innovation in secondary use of health data in the European Health Data Space (EHDS)
• Per- and Poly-fluoroalkyl substance (PFAS) exposure, emissions, and end of life management in the healthcare sector

HI call 9 will be a single-stage, applicant driven call with five topics aligned with the five specific objectives set out in the IHI Strategic Research and Innovation Agenda (SRIA). For this call, we want applicants to explore the SRIA and identify untapped opportunities that could be transformed into public-private projects through IHI. Read the draft call 9 text.

The objective of this call for tender is to strengthen the scientific evidence on the immune response provided by the Modified Vaccinia Ankara virus-Bavarian Nordic (MVA-BN) vaccine, with particular emphasis on the need and optimal timing of booster doses.

EDCTP3 calls 2025 (pre-proposals):

• Vaccines for reducing the disease burden of tuberculosis in sub-Saharan Africa
• Malaria therapeutics and clinical development of new antimalarial candidates (RIA)
• Accelerating the development of prophylactic vaccines against neglected tropical diseases (RIA)
• Strategic training hubs for fellowships in public health (CSA)
• Strengthening the regional networks of excellence and epidemic preparedness consortia (CSA)
• Tackling diarrhoeal diseases in the context of climate and health transformative innovations (RIA)
• Transformative innovations in global health (RIA)

 See the Q&A Global Health EDCTP3 – WP 2025

The cooperation on lung cancer is expected to generate new data and findings on lung cancer screening and mortality, and to provide guidance to Member States that are rolling out or planning to implement lung cancer screening programmes.

Under the EU-USA collaboration on cancer, two technical working groups have been established,

• one focusing on paediatric cancer and
• the other on lung cancer

This action will support the Europe’s Beating Cancer Plan by seeking synergies between the USA Cancer Moonshot Initiative, and Europe's Beating Cancer Plan and the EU Cancer Mission

The EP PerMed Venture Creation Programme will provide guidance by experienced mentors, ensuring that each project is mentored on its journey. By equipping researchers with robust business validation techniques and strategic insights, we guide them so their pioneering work can reach the market effectively, benefiting patients and driving forward the field of Personalised Medicine.

The EP PerMed Fast Track Validation Programme is open to start-ups and small teams, seeking to incorporate into a start-up, who are looking to advance their PM innovations through rigorous validation studies. The programme targets solutions that are at least at the proof-of-concept stage (TRL3).

Pre-proposal

ERA4Health brings the opportunity to increase European transnational collaborative research funding by creating a funding body for joint programming. Under this umbrella, ERA4Health is glad to pre-announce the launch of its sixth joint transnational call “InterHeart” 

Pre-proposal

Call for Proposals for Multinational and Translational Research Projects on "Interdisciplinary approaches to the neuroscience of pain"

PND launches this joint transnational call for with the aim of improving the well-being of people with neurodegenerative diseases through social sciences and humanities research.

The objective of this action is to set up and operate a support centre to advance the adoption of the European electronic health record exchange Format (EEHRxF) and key aspects such as the interoperability and security of EHR systems towards the implementation of the European health data space (EHDS). The support centre will provide services to implementers intending to ensure compatibility of their systems with the EHDS requirements.

Pre-proposal

The call concerns on research projects in human health on pharmacogenomic strategies for personalised medicine approaches that address :

• identification of new pharmacogenomic markers or signatures using (multi)-omics data in relation to drug or drug combination.
• validation of a pharmacogenomic marker or signatures using (multi)-omics data in predicting drug or drug combination outcomes.
• use pharmaco-omics strategies to determine the right dosage, the efficacy of treatments and/or the risk of adverse drug response and non-response to treatment to tailor personalised treatment pathways, including combined treatments (multi-medication).

Research projects in all disease areas will be welcome.

Pre-proposal

Joint Transnational Call 2025: “Pre-clinical therapy studies for rare diseases using small molecules and biologicals – development and validation”

Research studies on therapies using small molecules, small non-coding chemically synthesized nucleic acid-based therapies, repurposed drugs or biologicals (e.g., antibodies or proteins such as enzymes, immune modulators or growth factors etc.).

• HORIZON-MISS-2024-CIT-01-02: Changing urban spaces and mindsets to accelerate the transition to climate neutrality